Shire spent $260 million to acquire two liver diseases drugs from lumena pharmaceutical
-
Last Update: 2014-05-13
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: Biovalley 2014-5-13 UK pharmaceutical company shire pharmaceutical announced on May 12 that it will spend at least $260 million to acquire lumena pharmaceutical in the United States The transaction will enable shire to obtain two rare liver diseases drugs, enhance the company's rare disease product portfolio and strengthen its gastrointestinal disease business So far, shire has attracted Allergan's interest Shire will help lumena advance the phase III clinical development and marketing of two liver drugs The two drugs were acquired from Pfizer and Sanofi three years ago The first drug is currently in seven phase II studies investigating the treatment of four different diseases caused by high levels of bile acid The second drug was developed for the treatment of nonalcoholic fatty liver (NASH) Shire will make an advance payment of US $260 million in cash and the related clinical milestone payment.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
